Johnson & Johnson
JOHNSON & JOHNSON (Form: 8-K, Received: 10/01/2010 11:28:53)


Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):  September 27, 2010

(Exact name of registrant as specified in its charter)

New Jersey
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)

One Johnson & Johnson Plaza, New Brunswick, New Jersey  08933
(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code:  732-524-0400

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Item 8.01.  Other Events.

On September 27, 2010, the Company issued a press release to announce the completion of the acquisition of Micrus Endovascular Corporation, a global developer and manufacturer of minimally invasive devices for hemorrhagic and ischemic stroke.  The Company's press release dated September 27, 2010 is attached as Exhibit 99.1 to this Report.

Item 9.01.  Financial Statements and Exhibits.

(d) Exhibits.
Exhibit No.         Description

99.1              Press release dated September 27, 2010.


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Johnson & Johnson
Date:  October 1, 2010
Douglas K. Chia


Exhibit 99.1

  Media Contacts   I nvestor Relations Contacts
  Johnson & Johnson      Johnson & Johnson
 Bill Price    Louise Mehrotra
 732.524.6623  732.524.6491
  Codman & Shurtleff, Inc. Leslie Fishman
 Kelly Leadem  732.524.3922

Johnson & Johnson Completes Acquisition of Micrus Endovascular
Micrus Becomes Part of Codman Neurovascular
New Brunswick, NJ (September 27, 2010) – Johnson & Johnson (NYSE: JNJ) today announced that it has completed the acquisition of Micrus Endovascular, a global developer and manufacturer of minimally invasive devices for hemorrhagic and ischemic stroke. Johnson & Johnson announced its agreement to acquire Micrus on July 12, 2010.

Micrus Endovascular will operate under Codman Neurovascular, a business unit of Codman & Shurtleff, Inc., the global neurosurgery device company of the DePuy Family of Companies within Johnson & Johnson. Codman Neurovascular and Micrus offer innovative and complementary products and technologies for treating cerebral aneurysms, which can lead to stroke, the third leading cause of death in the United States, behind heart disease and cancer.[1]

The Codman Neurovascular portfolio includes bare platinum coils, vascular reconstruction devices (VRDs) and access devices, and the Micrus portfolio includes enhanced bioactive coil devices, balloon catheters, delivery systems and stents for the treatment of intracranial stenosis.

"Codman and Micrus are coming together to create one of the broadest portfolios and one of the deepest pipelines in the neurovascular industry," said P. Laxmin Laxminarain, Worldwide President, Codman & Shurtleff. "There are significant unmet needs in the treatment of neurovascular disease, and our hope is that by bringing these companies together, we can fuel rapid and meaningful innovation that further improves patient care, outcomes and access to treatment."

Codman Neurovascular and Micrus Endovascular will work together to provide a strong suite of solutions for hemorrhagic stroke, with many promising products in development for ischemic stroke. The World Health Organization (WHO) calls neurological disorders, which affect about 1.7 billion people, one of the greatest threats to public health. Each year, approximately 800,000 people in the U.S. experience a stroke. [2]

About Codman & Shurtleff, Inc.

Codman & Shurtleff is a global neuroscience and neurovascular company that develops and markets a wide range of products and solutions for the diagnosis and treatment of neurological disorders including chronic pain management, adult and pediatric hydrocephalus, neuro critical care, aneurysm and stroke prevention and management. Codman & Shurtleff is part of the DePuy Family of Companies within Johnson & Johnson. The DePuy Family of Companies has a rich heritage of pioneering a broad range of products and solutions across the continuum of orthopaedic and neurological care. These companies are unified under one vision – Never Stop Moving ™ – to express their commitment to bring meaningful innovation, shared knowledge and quality care to patients throughout the world. Visit for more information.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 3, 2010. Copies of this Form 10-K, as well as subsequent filings, are available online at, or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)

[2] National Stroke Association, “Stroke 101”, 2010.